Opko Health Inc
Analysts Drastically Reduced Target Price for Opko Health in March
Wall Street analysts expect an upside potential of 107.39% for Opko Health (OPK) based on the company’s closing price on March 26.
Here Are Opko Health’s Major R&D Programs in 2018
Opko Health (OPK) is focused on advancing multiple research and development (or R&D) programs including label expansion of Rayaldee and the development of novel therapies in 2018.
A Look at Opko Health’s Expense Projections for 2018
In its third-quarter earnings conference call, Opko Health (OPK) has forecasted its total costs and expenses for the fourth quarter to fall in the range of $280 million and $290 million.
Rayaldee Is a Key Revenue Driver for Opko Health
In its third-quarter earnings conference call, Opko Health (OPK) forecasted its total product revenues to fall in the range of $28 million to $32 million in the fourth quarter.
Men’s Health Is a Key Focus Area for Opko Health
Opko Health (OPK) is focused on advancing the penetration of its 4Kscore blood test.
What Analysts Recommend for Opko Health in November
In the third quarter, Opko Health reported revenues of $249.81 million, which is a YoY rise of 1.53%.
OPKO Health Expects Its Loss per Share to Shrink This Year
In the third quarter, OPKO Health (OPK) expects research and development expenses of $33 million–$38 million, and foresees its total operating expenses falling to $285 million–$305 million.
OPKO Health’s Q3 2018 Revenue Expectations
In the third quarter, OPKO Health (OPK) expects service revenue of $200 million–$220 million, assuming stable reimbursement rates and a small rise in volumes.
Opko Health: Q2 Expenditures, Developments, Recommendations
Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.
How Opko Health Fared in the Second Quarter of 2018
Opko Health (OPK) generated net revenues of $263.7 million in the second quarter of 2018 compared to $292.6 million in Q2 of 2017.
Why Citius Pharmaceuticals Stock Rose 31% in Week Ended July 13
In the week ended July 13, Citius Pharmaceuticals (CTXR) stock rose 31% to $3.09, from $2.35 on July 6. Since July 10, it has grown consistently.
Rayaldee Could Boost Opko Health’s Revenue in 2018 and Beyond
Opko Health’s (OPK) Rayaldee generated revenues of $3.7 million in the first quarter. Rayaldee had a solid uptake that quarter.
Wall Street Analysts: Mostly Positive on Opko Health in July
On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.
How Amgen’s Nephrology Drugs Are Positioned after 2Q17?
In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.
Why Quest Diagnostics’ Five Point Business Strategy Matters in 2016
If Quest Diagnostics succeeds in implementing its five-point business strategy going forward, it should boost the company’s share price and USMV.
Inside Quest Diagnostics’ Growth Restoration Strategy
Quest Diagnostics has been focusing on developing sales and marketing expertise, increasing esoteric testing, and building relationships with hospitals.
Covance Drug Development Drives LabCorp’s 1Q16 Revenue Growth
In 1Q16, LabCorp’s (LH) contract research organization business, Covance Drug Development, accounted for 30.7% of the company’s total revenues.
LabCorp’s Growth Drivers in 1Q16: Organic Growth, Acquisitions
In 1Q16, LabCorp’s (LH) national clinical laboratory business, LabCorp Diagnostics, accounted for 69.3% of the company’s total revenues.
Revenue Growth Initiatives Drove LabCorp’s Performance in 1Q16
In 1Q16, LabCorp (LH) reported strong revenue and earnings growth due to the effective implementation of multiple strategic initiatives. LabCorp is the world’s leading healthcare diagnostics company.
Must-Read Notes on LabCorp’s 1Q16 Earnings and Conference Call
Since the release of its 4Q15 earnings results, LabCorp has witnessed a solid 15.2% rise in its share price from $108.60 on February 18, 2016, to $125.10 on April 25, 2016, mainly due to strong business fundamentals.
XBI News as of March 16: Mid-Caps Under Pressure
Given selling pressures, XBI’s 18 mid-cap stocks went down marginally on average, losing 0.4% on March 16. Eight stocks advanced while ten stocks declined.
XBI on a Downward Slope, but How Steep?
On March 16, pressure on biotech and healthcare continued, with the SPDR S&P Biotech ETF (XBI) losing another 1.2% that day and closing at $48.31.
Analyzing Juno Therapeutics’ Performance until September 2015
Juno Therapeutics (JUNO) is a mid-cap stock with a market cap of ~$4.75 billion. The stock rose by 8.6%. It outperformed all of the biotech stocks.
Seattle Genetics Leads XBI Mid-Cap Stocks
Seattle Genetics (SGEN) rose 14.56% for the week ended September 11, 2015. The stock closed at $45.01 and moved back to 20-day, 50-day, and 100-day moving averages.
XBI Stocks: 33% Are Trading above the 20-Day Moving Averages
XBI fell substantially in the moving averages. From August 10–17, 2015, only 32.63% of the stocks were trading above the 20-day moving averages.
IBB Outperforms XBI: Top 10 Mid-Cap Stocks
The top ten mid-cap stocks from IBB outperformed the top ten mid-cap stocks from the SPDR S&P Biotechnology ETF (XBI) for the week ending August 7.